JP2013538555A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538555A5
JP2013538555A5 JP2013519216A JP2013519216A JP2013538555A5 JP 2013538555 A5 JP2013538555 A5 JP 2013538555A5 JP 2013519216 A JP2013519216 A JP 2013519216A JP 2013519216 A JP2013519216 A JP 2013519216A JP 2013538555 A5 JP2013538555 A5 JP 2013538555A5
Authority
JP
Japan
Prior art keywords
complex
isolated
mhc class
gad
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013519216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538555A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2011/000564 external-priority patent/WO2012007951A1/en
Publication of JP2013538555A publication Critical patent/JP2013538555A/ja
Publication of JP2013538555A5 publication Critical patent/JP2013538555A5/ja
Pending legal-status Critical Current

Links

JP2013519216A 2010-07-15 2011-07-14 Mhcクラスiiとグルタミン酸デカルボキシラーゼ(gad)自己抗原性ペプチドとの天然型複合体に対するt細胞受容体様特異性を有する単離された高親和性実体 Pending JP2013538555A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36444310P 2010-07-15 2010-07-15
US61/364,443 2010-07-15
PCT/IL2011/000564 WO2012007951A1 (en) 2010-07-15 2011-07-14 Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides

Publications (2)

Publication Number Publication Date
JP2013538555A JP2013538555A (ja) 2013-10-17
JP2013538555A5 true JP2013538555A5 (cg-RX-API-DMAC7.html) 2014-08-28

Family

ID=44504048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013519216A Pending JP2013538555A (ja) 2010-07-15 2011-07-14 Mhcクラスiiとグルタミン酸デカルボキシラーゼ(gad)自己抗原性ペプチドとの天然型複合体に対するt細胞受容体様特異性を有する単離された高親和性実体

Country Status (6)

Country Link
US (1) US9695410B2 (cg-RX-API-DMAC7.html)
EP (1) EP2593551B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013538555A (cg-RX-API-DMAC7.html)
BR (1) BR112013000985A2 (cg-RX-API-DMAC7.html)
CA (1) CA2805479A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012007951A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2805479A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
EP3301107B1 (en) * 2011-04-05 2020-05-06 Curara AB Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment
LT3590332T (lt) 2011-10-28 2022-08-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
JP6456350B2 (ja) * 2013-03-11 2019-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. キメラ主要組織適合複合体(mhc)クラスii分子を発現する遺伝子導入マウス
DK3280257T3 (da) 2015-04-06 2023-09-04 Regeneron Pharma Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr
KR20170034701A (ko) * 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물
DK3558339T5 (da) 2016-12-22 2024-09-02 Cue Biopharma Inc T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
TW201925235A (zh) * 2017-09-07 2019-07-01 美商信號生物製藥公司 具有化學結合位點之抗原呈現多肽及其使用方法
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
EP3935080A4 (en) * 2019-03-06 2023-04-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2020180501A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory antigen-presenting polypeptides and methods of use thereof
PL4010007T3 (pl) * 2019-08-09 2024-04-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Wytwarzanie kompleksów mhc ii/cii
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
AU2022249328A1 (en) 2021-03-31 2023-09-21 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
WO2025021112A1 (zh) * 2023-07-24 2025-01-30 佳吾益(北京)科技有限公司 开发mhc新抗原的工程化细胞
CN119039446B (zh) * 2024-10-30 2025-01-28 首都医科大学宣武医院 抗gad65抗体及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6060309A (en) * 1995-06-07 2000-05-09 Anergen, Inc. Immune mediators and related methods
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
DE19525784A1 (de) 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
KR19990063648A (ko) 1995-09-21 1999-07-26 프레드한 아룬디프 에스 글루타민산 데카복실라제에 대한 항체와 폴리(에틸렌 글리콜)공액물을 섬세포에 제공하는 방법
US6037137A (en) 1997-02-20 2000-03-14 Oncoimmunin, Inc. Fluorogenic peptides for the detection of protease activity
AU741130B2 (en) 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20030166277A1 (en) 2000-04-12 2003-09-04 University Of Rochester Targeted vaccine delivery systems
AU2001293735B2 (en) 2000-08-14 2006-05-25 N.V. Organon Use of antibodies against specific MHC-peptide complexes
EP1578775A4 (en) * 2002-07-12 2009-02-11 Dana Farber Cancer Inst Inc NEW COMPOSITIONS AND METHOD FOR GENERATING MHC CLASS II COMPOUNDS BY PEPTIDE EXCHANGE
ES2559409T3 (es) 2003-09-05 2016-02-12 Oregon Health & Science University Moléculas de MHC recombinantes monoméricas útiles para la manipulación de células T específicas de antígenos
CA2574665C (en) 2004-07-23 2014-07-15 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostic agents
CA2638892A1 (en) 2005-03-18 2006-09-28 Oregon Health & Science University Recombinant mhc molecules useful for manipulation of antigen-specific t cells
EP3269384A1 (en) 2007-03-07 2018-01-17 Uti Limited Partnership Compositions and methods for the prevention and treatment of autoimmune conditions
US20110008382A1 (en) 2009-03-07 2011-01-13 Burrows Gregory G Compositions and methods using recombinant MHC molecules for the treatment of uveitis
CA2805479A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
CA2805478A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands

Similar Documents

Publication Publication Date Title
JP2013538555A5 (cg-RX-API-DMAC7.html)
JP2013535963A5 (cg-RX-API-DMAC7.html)
US20220380445A1 (en) Serum albumin binders
JP7195142B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP2012518425A5 (cg-RX-API-DMAC7.html)
US20200283517A1 (en) Methods for treating chron's disease using an anti-il23 antibody
JP2012531212A5 (cg-RX-API-DMAC7.html)
JP2018527884A5 (cg-RX-API-DMAC7.html)
RU2013107776A (ru) Антитело к противоопухолевому антигену и способы применения
JP2018512145A5 (cg-RX-API-DMAC7.html)
JP2017529067A5 (cg-RX-API-DMAC7.html)
JP2013514788A5 (cg-RX-API-DMAC7.html)
RU2015141418A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2019512207A5 (cg-RX-API-DMAC7.html)
JP2010529026A5 (cg-RX-API-DMAC7.html)
CA3107001A1 (en) Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
JP2014515600A5 (cg-RX-API-DMAC7.html)
EP3716949A1 (en) Methods of treating autoimmune disease
JP2022524204A (ja) 自己抗体介在性自己免疫疾患の処置のための、抗cd38抗体及びその医薬組成物
RU2015129655A (ru) Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела
JP2017536821A5 (cg-RX-API-DMAC7.html)
JP2008506358A5 (cg-RX-API-DMAC7.html)
JP2013508391A5 (cg-RX-API-DMAC7.html)
Gross et al. CD19× CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease
JPWO2021119551A5 (cg-RX-API-DMAC7.html)